Key Details
Price
$0.00Annual EPS
-$1.69Annual ROE
4422.69%Annual Debt To Equity
-16.55Beta
-2.10Events Calendar
Next earnings date:
Nov 29, 2024Recent quarterly earnings:
Nov 09, 2023Recent annual earnings:
Mar 30, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
NEW YORK--(BUSINESS WIRE)--Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.
Better Therapeutics, Inc. (NASDAQ:BTTX ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Mark Heinen - Chief Financial Officer Frank Karbe - President and CEO Diane Gomez - Chief Commercial Officer Mark Berman - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Keay Nakae - Chardan Rahul Rakhit - LifeSci Capital Operator Good day and thank you for standing by, and welcome to the Better Therapeutics' Second Quarter 2023 Update Call. At this time all participants are in a listen-only mode.
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its second quarter 2023 financial results after the market closes on Wednesday, August 09, 2023. Management will host a conference call and webcast to provide a business update at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 09, 2023. To access the conference call, please register at: https://re.
Better Therapeutics (NASDAQ: BTTX ) stock is taking off on Tuesday as investors react to approval from the FDA for a Type 2 diabetes treatment. This covers AspyreRx, which is a prescription-only digital therapeutic treatment for patients 18 and older with Type 2 diabetes.
Better Therapeutics, Inc. (NASDAQ:BTTX ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Mark Heinen - CFO Frank Karbe - President and CEO Diane Gomez - Chief Commercial Officer Mark Berman - Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Lucas Romanski - TD Cowen Keay Nakae - Chardan Keay Rahul Rakhit - LifeSci Capital Operator Good morning and thank you for standing by, and welcome to the Better Therapeutics' First Quarter 2023 Conference Call. At this time all participants are in a listen-only mode.
Better Therapeutics, Inc. (BTTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
FAQ
- What is the primary business of Better Therapeutics?
- What is the ticker symbol for Better Therapeutics?
- Does Better Therapeutics pay dividends?
- What sector is Better Therapeutics in?
- What industry is Better Therapeutics in?
- What country is Better Therapeutics based in?
- When did Better Therapeutics go public?
- Is Better Therapeutics in the S&P 500?
- Is Better Therapeutics in the NASDAQ 100?
- Is Better Therapeutics in the Dow Jones?
- When was Better Therapeutics's last earnings report?
- When does Better Therapeutics report earnings?
- Should I buy Better Therapeutics stock now?